

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	CROSSMAN, A., <i>ET AL.</i>)	
SERIAL NO.:	10/527,271)	EXAMINER: JAVANMARD, S.
FILED:	MARCH 8, 2005)	ART UNIT: 1627
TITLE:	TREATMENT OF BASAL GANGLIA-RELATED MOVEMENT DISORDERS WITH 2,3-BENZODIAZEPINES)	CONFIRMATION NO.: 3503

VIA EFS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO FINAL OFFICE ACTION

Sir:

This paper is mailed in response to the Final Office Action mailed on December 17, 2009. A Petition for a three-month Extension of Time, Request for Continued Examination (RCE), and Invention Disclosure Form are filed herewith. Additionally filed herewith (and listed on the Invention Disclosure Form) are two references referred to in the remarks, below (Tarnawa 1998 and Solyom 2002).

Amendments to and a listing of the claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.